Clonidine

BRAND NAMES

• Catapres – immediate-release oral tablets (classic antihypertensive form) 
• Catapres-TTS – transdermal patch formulation (slow-release skin patch) 
• Kapvay – extended-release tablets, mainly used for ADHD 
• Duraclon – epidural formulation used in pain management (more specialized use)

MECHANISM OF ACTION

Clonidine is a centrally acting antihypertensive drug that works as an alpha-2 adrenergic receptor agonist. It stimulates alpha-2 receptors in the brainstem, which reduces sympathetic nervous system outflow and decreases the release of norepinephrine. This leads to lowered peripheral vascular resistance, reduced heart rate, and a fall in blood pressure.

PHARMACOKINETICS

Absorption 

Clonidine is well absorbed after oral administration, with good bioavailability of around 70–80%. Peak plasma levels occur within 1–3 hours after ingestion. It is also available as a transdermal patch that provides slow, continuous absorption over several days, helping maintain steady drug levels in the body.

Distribution

Clonidine is widely distributed in the body due to its moderate lipophilicity, allowing it to cross the blood–brain barrier easily. Its volume of distribution is approximately 2–3 L/kg, indicating extensive tissue uptake beyond the vascular compartment. It also shows good penetration into the central nervous system, which contributes to its central antihypertensive effects.

Metabolism

Clonidine undergoes limited hepatic metabolism, with only a small portion of the drug being biotransformed in the liver. About 40–50% of an administered dose is metabolized, mainly to inactive metabolites, while the rest is excreted unchanged. Because metabolism is relatively minor, clonidine’s pharmacokinetics are less dependent on hepatic enzyme activity compared to many other drugs.

Elimination

Clonidine is mainly eliminated by the kidneys, with a significant portion excreted unchanged in urine. It has an elimination half-life of about 12–16 hours, which allows for once or twice daily dosing depending on the formulation. In patients with renal impairment, the drug may accumulate, so dose adjustment may be required.

PHARMACODYNAMICS

Clonidine is a centrally acting α2-adrenergic agonist that reduces sympathetic outflow from the brain. By stimulating α2 receptors in the brainstem, it decreases norepinephrine release, leading to reduced peripheral vascular resistance, lowered heart rate, and decreased blood pressure. It also produces sedative and anxiolytic effects due to reduced central noradrenergic activity. At higher doses, it may slightly activate peripheral α2 receptors, but its primary pharmacodynamic effect is central sympatholysis.

ADMINISTRATION

Clonidine is administered mainly by the oral route as immediate-release or extended-release tablets for hypertension and ADHD. It is also available as a transdermal patch that provides continuous drug delivery over one week. In some specialized settings, it can be given epidurally for pain management. The choice of route depends on the clinical indication and required duration of action.

DOSAGE AND STRENGTH

Oral tablets (immediate-release): commonly 0.1 mg, 0.2 mg, and 0.3 mg, usually started at low doses and titrated based on blood pressure response.
Extended-release tablets (Kapvay): 0.1 mg and 0.2 mg, mainly used for ADHD, often given once or twice daily.
Transdermal patch: delivers approximately 0.1 mg/day, 0.2 mg/day, or 0.3 mg/day over 7 days.
Epidural formulation: typically 0.1–0.2 mg/mL, used in controlled hospital settings for pain management.

DRUG INTERACTIONS

Clonidine interacts with CNS depressants like alcohol, opioids, and sedatives, increasing drowsiness and hypotension. It can have additive effects with other antihypertensives, causing excessive blood pressure lowering. Beta-blockers require careful management to avoid rebound hypertension on withdrawal, and tricyclic antidepressants or sympathomimetics may reduce its effect. Monitoring blood pressure is important when using interacting drugs.

FOOD INTERACTIONS

Clonidine has minimal direct food interactions, so it can generally be taken with or without food. However, alcohol should be avoided because it can enhance its sedative and hypotensive effects, leading to increased dizziness or drowsiness.

CONTRAINDICATIONS

Clonidine is contraindicated in patients with hypersensitivity to the drug and should be avoided in those with severe bradycardia or advanced AV block without a pacemaker. It is also not recommended in severe hypotension, as it can further lower blood pressure and worsen the condition.

SIDE EFFECTS

• Dry mouth

• Drowsiness

• Dizziness

• Fatigue

• Constipation

• Hypotension

• Bradycardia

OVER DOSE 

• Severe drowsiness 

• Hypotension 

• Bradycardia 

• Respiratory depression 

• Coma (in severe cases)

TOXICITY

Clonidine toxicity occurs due to excessive α2-adrenergic stimulation, leading to central nervous system and cardiovascular depression. It presents with severe drowsiness, hypotension, bradycardia, respiratory depression, and sometimes coma, resembling opioid toxicity